Q-omics provides the consensus-scored UBASH3A profile across patient tissues and cancer cell-line models. UBASH3A expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, UBASH3A is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, UBASH3A RNA expression shows 16,626 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, KIRC, and LSCC as cancer lineages where UBASH3A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UBASH3A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UBASH3A survival associations across molecular data types. UBASH3A RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UBASH3A RNA expression–survival associations across cancer types. High UBASH3A expression shows unfavorable associations in UVM, but favorable associations in HNSC, SKCM, UCEC, CESC and LIHC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for UBASH3A RNA expression.
This table summarizes UBASH3A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for UBASH3A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UBASH3A shows lower tumor expression in COAD, LUSC, THCA and BLCA and higher tumor expression in KIRC and STAD. The KIRC box plot shows higher UBASH3A RNA expression in tumor versus normal tissue (log2 FC = +1.375, t-test p < 0.001).
This table shows molecular features associated with UBASH3A in patient tissues and cancer cell lines. In patient samples, UBASH3A shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, UBASH3A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BLOOD_Leukemia.
